Trial Details
Not recruitingBasic Information
| Clinical ID | c3275 |
|---|---|
| Identifier | NCT01009281 |
| Trial Title | A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Crohn's Disease;Inflammatory Bowel Disease |
| Interventions | Drug: AIN457 |
Participant Information
| Sponsor | Novartis Pharmaceuticals |
|---|---|
| City | - |
| Country/Region | United States;Austria;Canada;Germany;Poland |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |